Abstract and Introduction
Introduction
More than a dozen methylphenidate preparations are currently available in the United States for the treatment of attention-deficit/hyperactivity disorder (ADHD), each offering a difference in the pattern of drug release and duration of symptom control that may prove advantageous for an individual patient and family. The most recent addition, delayed-release and extended-release methylphenidate (DR/ER MPH) capsules (Jornay PM™) was approved by the Food and Drug Administration (FDA) on August 10, 2018 as the first product designed for administration at bedtime.[1] This new product was developed to avoid the up to 2 hour delay in early morning ADHD symptom control that may occur with other extended-release MPH products. It is currently approved for patients ages 6 years and older, and is designed to be given at approximately 8:00 pm to provide effective symptom control upon awakening.[1–4]
Pediatr Pharm. 2019;25(3) © 2019 University of Virginia
